|
On April 30, 2007 GeneraMedix Inc. received
approval from the U.S. Food and Drug Administration (FDA)
for its Abbreviated New Drug Applications (ANDAs) for Methotrexate
Injection, USP. GeneraMedix will market Methotrexate 25
mg/mL in 2 mL, 10 mL and 40 mL vials. The product is AP
rated and equivalent to the reference listed drugs of Bedford
Laboratories and Mayne Pharma (USA) Inc.
For product information please contact:
GeneraMedix Inc. Customer Service
1-866–GENERA–1
(1-866-436-3721)
|
